# Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

> **NCT00742144** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 6 (actual)

## Conditions studied

- Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular

## Interventions

- **DRUG:** ofatumumab

## Key facts

- **NCT ID:** NCT00742144
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-19
- **Primary completion:** 2009-11-18
- **Final completion:** 2009-11-18
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2017-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00742144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00742144, "Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00742144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*